Figure 5.

Improvement of the symptoms of atopic dermatitis by oral administration of ST-miRCCL22 in mice. (A) The skin of ST-miRCCL22-treated mice showed greater improvement when compared to the PBS or ST-miRCV groups. (B) The total scratch counts of ST-miRCCL22-treated mice were dramatically lower compared with the PBS or ST-miRCV groups. ^*P < 0.05, when comparing the ST-miRCCL22 group with the ST-miRCV-control group (n = 10). These experiments were repeated at least three times with similar results. (C) Histological analyses were performed to examine the reduced inflammation due to ST-miRCCL22. Histological samples were collected seven days after oral inoculation with 10⁸ bacterial cells. Mice were treated with PBS, ST-miRCV and ST-miRCCL22. As shown with H/E staining, skin tissue demonstrated reduced inflammation when compared to the skin of control mice treated with ST-miRCCL22.